Can a simple arthritis drug tame CAR-T's brain risks?
NCT ID NCT04150913
First seen Dec 26, 2025 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tested whether adding the drug anakinra to standard CAR-T cell therapy could reduce serious brain side effects in people with relapsed or refractory non-Hodgkin lymphoma. Fifteen participants received the combination. The goal was to see if anakinra could lower the rate of neurotoxicity without harming the cancer-fighting effect of CAR-T cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.